ACADIA PHARMACEUTICALS INC (ACAD)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-04-07

Key Insights

The reporting person, James Kihara, who serves as the Principal Accounting Officer of ACADIA Pharmaceuticals Inc., exercised 2,010 restricted stock units and subsequently sold 1,030 shares to cover tax withholding obligations.
The insider sale was made pursuant to a 10b5-1 trading plan, indicating a systematic approach to managing their equity position.
The insider continues to hold a significant direct ownership stake of 27,865 shares in the company, suggesting ongoing commitment and alignment with shareholder interests.

Insider Trading Filed: 2026-04-07

Key Insights

Insider Mark Schneyer, the EVP and Chief Financial Officer, acquired 5,276 shares of ACADIA Pharmaceuticals through the vesting of restricted stock units, increasing his direct ownership to 62,836 shares.
Schneyer also sold 2,709 shares at $22.2 to cover withholding taxes, indicating a partial liquidation of his position.
The restricted stock units vest over four years, with the first tranche vesting on April 5, 2023, suggesting continued equity incentives and alignment with shareholders.

Insider Trading Filed: 2026-03-26

Key Insights

The reporting person, Mark C. Schneyer, exercised restricted stock units (RSUs) and subsequently sold a portion of the acquired shares to cover withholding taxes, indicating routine management of equity compensation.
The timing and amounts of the RSU vesting and share sales suggest ongoing equity-based incentive and retention programs for this executive officer.
The reporting of these transactions in a timely manner through a Form 4 filing demonstrates the company's compliance with SEC insider reporting requirements.

Insider Trading Filed: 2026-03-26

Key Insights

The reporting person, James Kihara, who is the Principal Accounting Officer of ACADIA Pharmaceuticals Inc., has reported several transactions involving the company's common stock, including the acquisition of 1,627 and 2,142 shares through the vesting of restricted stock units, and the subsequent sale of 833, 1,097, and 12 shares to cover withholding taxes.
The transactions appear to be routine and part of the reporting person's compensation and stock ownership arrangement, as the reporting person still holds a significant number of shares (26,885) following the reported transactions.
The timing and volume of the transactions do not suggest any significant insider trading activity or changes in the reporting person's overall beneficial ownership position in the company.

Insider Trading Filed: 2026-03-26

Key Insights

Jennifer J. Rhodes, the EVP and Chief Legal Officer of ACADIA Pharmaceuticals, has exercised 7,515 restricted stock units (RSUs) and sold 3,844 shares of common stock to cover withholding taxes.
The RSUs vested in four equal annual installments starting on March 24, 2026, indicating ongoing executive compensation and equity incentives.
The sale of shares to cover taxes is a routine transaction and does not necessarily signal a change in the executive's outlook on the company.

Insider Trading Filed: 2026-03-26

Key Insights

The CEO, Catherine Owen Adams, exercised 23,509 restricted stock units and sold 11,641 shares of ACADIA Pharmaceuticals' common stock on March 24-25, 2026.
The sale of shares was made to cover withholding taxes and tax-related items, and was intended to comply with Rule 10b5-1(c)(1)(i)(B).
Following the transactions, the CEO still holds 14,803 shares of ACADIA Pharmaceuticals' common stock directly.

Current Report Filed: 2026-01-13

Key Insights

Acadia Pharmaceuticals anticipates 2025 net sales will exceed $1 billion, which is consistent with previous guidance and suggests strong financial performance.
The company provided an updated corporate slide presentation on its website, indicating transparent communication with investors.
No other material information or changes were reported in this 8-K filing, suggesting a routine update.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.